XOMA Royalty Discloses Strong Preliminary FY25 Results, $16M Share Buyback, and Ongoing Janssen Litigation

summarizeSummary

XOMA Royalty Corp reported strong preliminary FY2025 financials, including $49-50 million in royalty cash and a $16 million share repurchase, alongside disclosure of ongoing litigation against Janssen Biotech.

check_boxKey Events · Financing and Capital Events · XOMA

• Preliminary FY2025 Financial Update

  XOMA Royalty reported preliminary FY2025 cash receipts from royalties and milestones of approximately $49-50 million, with a year-end cash position of $133 million.

• Significant Share Repurchase

  The company repurchased and retired 648,048 common shares for $16.0 million during fiscal year 2025, demonstrating a substantial return of capital to shareholders.

• Janssen Litigation Disclosure

  XOMA Royalty disclosed an ongoing litigation against Janssen Biotech, Inc. concerning the unauthorized use of its intellectual property related to the drug TREMFYA, which contributed to a $1.0 million increase in G&A expenses for FY2025.

auto_awesomeAnalysis · XOMA · Life Sciences

XOMA Royalty Corp's 8-K filing, accompanied by an updated corporate presentation, reveals robust preliminary financial results for fiscal year 2025. The company reported preliminary cash receipts from royalties and milestones of approximately $49-50 million and a strong cash position of $133 million as of year-end 2025. Critically, XOMA Royalty repurchased 648,048 common shares for $16.0 million during FY2025, representing a significant return of capital to shareholders and signaling management's confidence. Additionally, the filing details an ongoing litigation against Janssen Biotech, Inc. for alleged unauthorized use of XOMA's intellectual property related to TREMFYA, which contributed to a $1.0 million increase in G&A expenses for FY2025. While the litigation outcome is uncertain, the substantial share buyback and healthy financials present a positive outlook for investors.